Podcasts about Invasive

In this episode, Justin and Rob are joined by Luc Myers to discuss what you should do with invasive species. Who will win? You decide. Reptile Fight Club!Follow Justin Julander @Australian Addiction Reptiles-http://www.australianaddiction.comIG https://www.instagram.com/jgjulander/Follow Rob @ https://www.instagram.com/highplainsherp/Follow MPR Network @FB: https://www.facebook.com/MoreliaPythonRadioIG: https://www.instagram.com/mpr_network/YouTube: https://www.youtube.com/channel/UCtrEaKcyN8KvC3pqaiYc0RQSwag store: https://teespring.com/stores/mprnetworkPatreon: https://www.patreon.com/moreliapythonradio

Budde, Joachim www.deutschlandfunk.de, Forschung aktuell

Invasive species are well known to damage ecosystems by directly eating other animals and disrupting the food chain. But their impacts can go much deeper, as a new study about seed dispersal by pythons and tegus in the Everglades has shown - they may be contributing to the destruction of rare and unusual habitats. Become a Patreon: https://www.patreon.com/herphighlights Merch: https://www.redbubble.com/people/herphighlights/shop Full reference list available here: http://www.herphighlights.podbean.com Main Paper References: Figueroa A, Davis KR, Harman MEA, Bartoszek IA, Easterling IC, Yackel Adams AA, Romagosa CM. 2025. Double agents: invasive Burmese pythons (Python bivittatus) and Argentine black and white tegus (Salvator merianae) as potential seed dispersers in South Florida. Journal of Zoology:jzo.70082. DOI: 10.1111/jzo.70082. Other Mentioned Papers/Studies: Harman MEA, Fuller NR, Baiser B, Blackburn JK, Li X, Currylow AF, Yackel Adams AA, Falk BG, Romagosa CM. 2025. Dietary breadth and ecological plasticity facilitate invasion potential in a large omnivorous lizard. Frontiers in Amphibian and Reptile Science 3:1635085. DOI: 10.3389/famrs.2025.1635085. Sapkota, A., Karki, A., Sapkota, K. R., & Baral, R. (2025). First record of death-feigning behavior in common wolf snake Lycodon aulicus (Linnaeus, 1758) from Nepal. Nepalese Journal of Zoology, 9(2), 85-88. Other Links/Mentions: AmphibiaWeb 2008 Acris gryllus: Southern Cricket Frog University of California, Berkeley, CA, USA. Accessed Feb 24, 2026. Acris gryllus from James W. Beck: https://amphibiaweb.org/cgi/amphib_query?special=call&genus=Acris&species=gryllus  Editing and Music: Intro/outro – Treehouse by Ed Nelson Species Bi-week theme – Michael Timothy Other Music – The Passion HiFi, https://www.thepassionhifi.com

A controversial new change could soon be coming to changerooms, and not everyone is happy about it. The team unpacks what’s been happening in some stores, why it’s causing such strong reactions, and whether people feel it crosses the line when it comes to privacy.See omnystudio.com/listener for privacy information.

In this podcast, experts Ashish M. Kamat, MD, MBBS, Katie S. Murray, DO, MS, and Thomas Powles, MD, MBBS, MRCP, discuss the classification of BCG responsiveness and intravesical and systemic therapies for non-muscle invasive bladder cancer.

The Everyday Environment team is back for a new season this spring to discuss Invasive species. Get a preview of what is in store as well as a primer on Invasive Species from everyone's favorite Extension person: Chris Evans.Invasives Species 101 starts at 20:30Original Episode from the archives: Invasive Alert: Spotted LanternflyShare your own Everyday ObservationWas there something about this topic we didn't cover? See something cool in nature? Let us know! Send us your question or share your everyday nature observation with us at go.illinois.edu/EEconnect, and we may share it in a future blog or podcast.Questions? We'd love to hear from you!Abigail Garofalo aeg9@illinois.edu, Erin Garrett emedvecz@illinois.edu, Amy Lefringhouse heberlei@illinois.edu Subscribe to our NewsletterCheck out our BlogSee the Everyday Environment Archives

What does “native” really mean — and who decides?In this episode of Garden Dilemmas, Mary Stone explores native vs. invasive plants, urban gardens, biodiversity, and ecosystem balance.From dandelions to the marmorated stink bug, this episode reflects on what belonging means in a rapidly changing landscape. Inspired by Point State Park in Pittsburgh and the writings of Peter Del Tredici, Mary examines novel ecosystems, adaptation, and how urban environments balance native and non-native plants.A thoughtful look at nature, resilience, and coexistence.Link to the Companion Post: Native vs. Invasive Plants: Who Decides?  May we tend wisely, welcome thoughtfully, and grow together. Related Stories & Helpful Links:·         Ep. 99 - Wonders of Witch Hazel·         Wonders of Witch Hazel - Blog Post·         Point State Park, an Urban Garden- Pittsburgh, PA ·         Ep 157. Benefits of Plantain & Dandelion 'Weeds'·         Benefits of Plantain & Dandelion “Weeds” - Blog Post8888I'd love to hear your garden and nature stories, as well as your thoughts on topics for future podcast episodes. You can email me at AskMaryStone@gmail.com.   You can follow Garden Dilemmas on Facebook and Instagram #MaryElaineStone.You can also listen on Apple Podcasts, Spotify, and your favorite podcast app.Thank you for sharing the Garden of Life, Mary Stone Columnist & Garden DesignerMore about the Podcast and Column: Welcome to Garden Dilemmas, Delights, and Discoveries. It's not only about gardens; it's about nature's inspirations, about grasping the glories of the world around us, gathering what we learned from Mother Nature, and carrying these lessons into our garden of life. So, let's jump in, in the spirit of learning from each other. We have lots to talk about. Thanks for tuning in, Mary Stone Garden Dilemmas? AskMaryStone.comDirect Link to Podcast Page

### Core Message Not every thought that enters the mind originates from oneself or from God. Many harmful, discouraging, or destructive thoughts are portrayed as external attacks intended to undermine identity, peace, joy, relationships, and calling. The central call is to take thoughts captive and align them with truth. ### Key Themes 1. Nature of Invasive Thoughts • These thoughts are sudden, unwanted, and often dark or discouraging. • They may involve fear, despair, self-condemnation, anger, or harm. • Having such a thought is not failure; dwelling on or acting on it is the danger. 2. Spiritual Framework • The sermon draws heavily from Scripture (notably Ephesians 6, John 10:10, 2 Corinthians 10, Philippians 4). • Invasive thoughts are described as “fiery darts” meant to steal peace, identity, confidence, joy, hope, and purpose. • The enemy’s strategy is isolation—breaking relationships and unity so individuals are more vulnerable. 3. Identity and Authority • Believers are reminded of their identity “in Christ,” emphasizing that condemnation and shame do not define them. • Confidence and authority come not from self-effort, but from humility and reliance on God. • The message stresses that God’s voice brings life, encouragement, and truth—never destruction. 4. How to Respond Practically • Recognize the thought: identify whether it aligns with God’s character. • Reject it: do not accept or “own” thoughts that contradict truth. • Replace it: actively substitute Scripture and truth rather than fixating on the negative thought. • Resist consistently: resistance causes the enemy to retreat, though vigilance is ongoing. 5. Community and Support • Openness and prayer within community are emphasized as protective. • Unity is portrayed as strength—like interlocking shields that prevent attack. • Isolation increases risk; honesty and shared prayer reduce it. ### Closing Emphasis Victory comes not from striving alone, but from standing in Christ. The sermon ends with encouragement: believers are “more than conquerors,” never alone, and equipped to guard their minds and hearts through truth, prayer, Scripture, and community.

Did you know that combining Bacillus Calmette-Guérin (BCG) with immunotherapy significantly improves outcomes in high-risk bladder cancer? Credit available for this activity expires: 2/24/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/immunotherapy-non-muscle-invasive-bladder-cancer-expert-2026a10005af?ecd=bdc_podcast_libsyn_mscpedu

Get ready to breathe easy with this lively Cribsiders episode on non-invasive respiratory support in pediatrics! We're joined by the incredible Dr. Michelle Perez from Montefiore, who breaks down the fundamentals of CPAP, BiPAP and HFNC. From choosing the right modality to knowing when it's time to escalate, this episode will help you support little lungs without jumping straight to the tube. 

Medical Notes: How Energy Drinks May Worsen Your Cancer, A Non-Invasive Treatment For Seizures, And How To Fight Against Procrastination  Are energy drinks making you sick? A new treatment for seizures may soon be possible without the need for invasive brain surgery. Good news for sugar addicts! Scientists have created a healthier sweetener using Tagatose. How to fight against procrastination.Host: Maayan Voss de Bettancourt Producer: Kristen Farrah Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cheatgrass has quietly become one of the biggest threats to western rangelands,  crowding out native forage, increasing wildfire risk, and costing ranchers valuable time, grass, and money. But there's reason for hope.This week, Haley sits down with Jaycie Arndt of IMAGINE (Institute for Managing Annual Grasses Invading Natural Ecosystems) to unpack the good, the bad, and the ugly of this fast-spreading invasive. From its origins and aggressive growth habits to practical management strategies and emerging research, Jaycie shares real-world solutions landowners can put to work today.If you care about protecting sagebrush country and the future of the American West, tune in for Part 1 of our cheatgrass deep dive, with Part 2 coming soon.Topics[0:00] Intro with Jaycie Arndt[1:05] What cheatgrass is and how it got to the West[6:40] How it spreads: livestock, equipment, disturbance, and fire[9:05] Can grazing actually help control cheatgrass?[14:00] Treatment costs + grants and agency funding options[16:30] The biggest mistake landowners make[19:00] Cheatgrass, wildfire cycles, and losing sagebrush country[24:30] Workshops, webinars, and where to find resources[27:10] Key takeaways + what landowners can do nextLinksIMAGINECheatgrass HandbookNeed professional help finding, buying or selling a legacy ranch, contact us: Mirr Ranch Group 901 Acoma Street Denver, CO 80204 Phone: (303) 623-4545 https://www.MirrRanchGroup.com/

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial septal defects in adults Conservative and invasive management of chronic coronary syndromes Milestones: 4S trial   Host: Rick Grobbee Guests: JP Carpenter, Annemien van den Bosch, Rasha Al-Lamee, Roxana Mehran Want to watch the episode? Go to: https://esc365.escardio.org/event/2552 Want to watch the extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; personal fees from: None ; Equity

Discover why hydrilla verticillata is nearly impossible to eradicate. From tubers that survive years in sediment to cyanobacteria linked to eagle deaths, this conversation reveals the hidden biology behind one of North America's most persistent aquatic invaders. Hydrilla.org City: San Diego Address: 982 Hood Avenue Website: https://hydrilla.org

JCO PO author Dr. Foldi at UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine shares insights into the JCO PO article, "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast." Host Dr. Rafeh Naqash and Dr. Foldi discuss how serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are thrilled to be joined by Dr. Julia Foldi, Assistant Professor of Medicine in the Division of Hematology-Oncology at University of Pittsburgh School of Medicine and the Magee-Womens Hospital of the UPMC. She is also the lead and corresponding author of the JCO Precision Oncology article entitled "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients with Metastatic Invasive Lobular Carcinoma of the Breast." At the time of this recording, our guest's disclosures will be linked in the transcript. Julia, welcome to our podcast, and thank you for joining us today. Dr. Julia Foldi: Thank you so much for having me. It is a pleasure. Dr. Rafeh Naqash: Again, your manuscript and project address a few interesting things, so we will start with the basics, since we have a broad audience that comprises trainees, community oncologists, and obviously precision medicine experts as well. So, let us start with invasive lobular breast carcinoma. I have been out of fellowship for several years now, and I do not know much about invasive lobular carcinoma. Could you tell us what it is, what some of the genomic characteristics are, why it is different, and why it is important to have a different way to understand disease biology and track disease status with this type of breast cancer? Dr. Julia Foldi: Yes, thank you for that question. It is really important to frame this study. So, lobular breast cancers, which we shorten to ILC, are the second most common histologic subtype of breast cancer after ductal breast cancers. ILC makes up about 10 to 15 percent of all breast cancers, so it is relatively rare, but in the big scheme of things, because breast cancer is so common, this represents actually over 40,000 new diagnoses a year in the US of lobular breast cancers. What is unique about ILC is it is characterized by loss of an adhesion molecule, E-cadherin. It is encoded by the CDH1 gene. What it does is these tumors tend to form discohesive, single-file patterns and infiltrate into the tumor stroma, as opposed to ductal cancers, which generally form more cohesive masses. As we generally explain to patients, ductal cancers tend to form lumps, while lobular cancers often are not palpable because they infiltrate into the stroma. This creates several challenges, particularly when it comes to imaging. In the diagnostic setting, we know that mammograms and ultrasounds have less sensitivity to detect lobular versus ductal breast cancer. When it comes to the metastatic setting, conventional imaging techniques like CT scans have less sensitivity to detect lobular lesions often. One other unique characteristic of ILC is that these tumors tend to have lower proliferation rates. Because our glucose-based PET scans depend on glucose uptake of proliferating cells, often these tumors also are not avid on conventional FDG-PET scans. It is a challenge for us to monitor these patients as they go through treatment. If you think about the metastatic setting, we start a new treatment, we image people every three to four cycles, about every three months, and we combine the imaging results with clinical assessment and tumor markers to decide if the treatment is working. But if your imaging is not reliable, sometimes even at diagnosis, to really detect these tumors, then really, how are we following these patients? This is really the unique challenge in the metastatic setting in patients with lobular breast cancer: we cannot rely on the imaging to tell if patients are responding to treatment. This is where liquid biopsies are really, really important, and as the field is growing up and we have better and better technologies, lobular breast cancer is going to be a field where they are going to play an important role. Dr. Rafeh Naqash: Thank you for that easy-to-understand background. The second aspect that I would like to have some context on, to help the audience understand why you did what you did, is ctDNA, tumor informed and non-informed. Could you tell us what these subtypes of liquid biopsies are and why you chose a tumor informed assay for your study? Dr. Julia Foldi: Yes, it is really important to understand these differences. As you mentioned, there are two main platforms for liquid biopsy assays, circulating tumor DNA assays. I think what is more commonly used in the metastatic setting are non-tumor informed assays, or agnostic assays. These are generally next-generation sequencing-based assays that a lot of companies offer, like Guardant, Tempus, Caris, and FoundationOne. These do not require tumor tissue; they just require a blood sample, a plasma sample, essentially. The next-generation sequencing is done on cell-free DNA that is extracted from the plasma, and it is looking for any cell-free DNA and essentially, figuring out what part of the cell-free DNA comes from the tumor is done through a bioinformatics approach. Most of these assays are panel tests for cancer-associated mutations that we know either have therapeutic significance or biologic significance. So, the results we receive from these tests generally read out specific mutations in oncogenic genes, or sometimes things like fusions where we have specific targeted drugs. Some of the newer assays can also read out tumor fraction; for example, the newest generation Guardant assay that is methylation-based, they can also quantify tumor fraction. But the disadvantage of the tumor agnostic approach is that it is a little bit less sensitive. Opposed to that, we have our tumor informed tests, and these require tumor tissue. Essentially, the tumor is sequenced; this can either be whole exome or whole genome sequencing. The newer generation assays are now using whole genome sequencing of the tumor tissue, and a personalized, patient-specific panel of alterations is essentially barcoded on that tumor tissue. This can be either structural variants or it can be mutations, but generally, these are not driver mutations, but sort of things that are present in the tumor tissue that tend to stay unchanged over time. For each particular patient, a personalized assay, if you want to call it a fingerprint or barcode, is created, and then that is what then is used to test the plasma sample. Essentially, you are looking for that specific cancer in the blood, that barcode or fingerprint in the blood. Because of this, this is a much more sensitive way of looking for ctDNA, and obviously, this detects only that particular tumor that was sequenced originally. So, it is much more sensitive and specific to that tumor that was sequenced. You can argue for both approaches in different settings. We use them in different settings because they give us different information. The tumor agnostic approach gives us mutations, which can be used to determine what the next best therapy to use is, while the tumor informed assay is more sensitive, but it is not going to give us information on therapeutic targets. However, it is quantified, and we can follow it over time to see how it changes. We think that it is going to tell us how patients respond to treatment because we see our circulating tumor DNA levels rise and fall as the cancer burden increases or decreases. We decided to use the tumor informed approach in this particular study because we were really interested in how to determine if patients are having response to treatment versus if they are going to progress on their treatment, more so than looking for specific mutations. Dr. Rafeh Naqash: When you think about these tumor informed assays and you think about barcoding the mutations on the original tumor that you try to track or follow in subsequent blood samples, plasma samples, in your experience, if you have done it in non-lobular cancers, do you think shedding from the tumor has something to do with what you capture or how much you capture? Dr. Julia Foldi: Absolutely. I think there are multiple factors that go into whether someone has detectable ctDNA or not, and that has to do with the type of cancer, the location, right, where is the metastatic site? This is something that we do not fully understand yet: what are tumors that shed more versus not? There is also clearance of ctDNA, and so how fast that clearance occurs is also something that will affect what you can detect in the blood. ctDNA is very short-lived, only has a half-life of hours, and so you can imagine that if there is little shedding and a lot of excretion, then you are not going to be detecting a lot of it. In general, in the metastatic setting, we see that we can detect ctDNA in a lot of cases, especially when patients are progressing on treatment, because we imagine their tumor burden is higher at that point. Even with the non-tumor informed assays, we detect a lot of ctDNA. Part of this study was to actually assess: what is the proportion of patients where we can have this information? Because if we are only going to be able to detect ctDNA in less than 50 percent of patients, then it is not going to be a useful method to follow them with. Because this field is new and we have not been using a lot of tumor informed assays in the metastatic setting, we did not really know what to expect when we set out to look at this. We did not know what was going to be the baseline detection rate in this patient population, so that was one of the first things that we wanted to answer. Dr. Rafeh Naqash: Excellent. Now going to this manuscript in particular, what was the research question, what was the patient population, and what was the strategy that you used to investigate some of these questions? Dr. Julia Foldi: So, we partnered with Natera, and the reason was that their Signatera tumor-informed assay was the first personalized, tumor-informed, really an MRD assay, minimal residual disease detection assay. It has been around the longest and has been pretty widely used commercially already, even though some of our data is still lacking. but we know that people are using this in the real world. We wanted to gather some real-world data specifically in lobular patients. So, we asked Natera to look at their database of commercial Signatera testing and look for patients with stage 4 lobular breast cancer. The information all comes from the submitting physicians sending in pathologic reports and clinical notes, and so they have that information from the requisitions essentially that are sent in by the ordering physician. We found 66 patients who were on first-line or close to first-line endocrine-based therapies for their metastatic lobular breast cancer and had serial collections of Signatera tests. The way we defined baseline was that the first Signatera had to be sent within three months of starting treatment. So, it is not truly baseline, but again, this is a limitation of looking at real-world data is that you are not always going to get the best time point that you need. We had over 350 samples from those 66 patients, again longitudinal ctDNA samples, and our first question was what is the baseline detection rate using this tumor informed assay? Then, most importantly, what is the concordance between changes in ctDNA and clinical response to treatment? That is defined by essentially radiologic response to treatment. Dr. Rafeh Naqash: Interesting. So, what were some of your observations in terms of ctDNA dynamics, whether baseline levels made a difference, whether subsequent levels at different time points made a difference, or subsequent levels at, let us say, cycle three made a difference? Were there any specific trends that you saw? Dr. Julia Foldi: So, first, at baseline, 95 percent of patients had detectable ctDNA, which is, I think, a really important data point because it tells us that this can be a really useful test. If we can detect it in almost all patients before they start treatment, we are going to be able to follow this longitudinally. And again, these were not true baseline samples. So, I think if we look really at baseline before starting treatment, almost all patients will have detectable ctDNA in the metastatic setting. The second important thing we saw was that disease progression correlated very well with increase in ctDNA. So, in most patients who had disease progression by imaging, we saw increase in ctDNA. Conversely, in most patients who had clinical benefit from their treatment, so they had a response or stable disease, we saw decrease in ctDNA levels. It seems that what we call molecular response based on ctDNA is tracking very nicely along with the radiographic response. So, those were really the two main observations. Again, this is a small cohort, limited by its real-world nature and the time points that ctDNA assay was sent was obviously not mandated. This is a real-world data set, and so we could not really look at specific time points like you asked about, let us say, cycle three of therapy, right? We did not have all of the right time points for all of the patients. But what we were able to do was to graph out some specific patient scenarios to illustrate how changes in ctDNA correlate with imaging response. I can talk a little bit about that. Dr. Rafeh Naqash: That was going to be my question. Did you see patients who had serial monitoring using the tumor informed ctDNA assay where the assay became positive a few months before the imaging? Did you have any of those kinds of observations? Dr. Julia Foldi: Yes, so I think this is where the field is going: are we able to use this technology to maybe detect progression before it becomes clinically apparent? Of course, there are lots of questions about: does that really matter? But it seems like, based on some of the patient scenarios that we present in the paper, that this testing can do that. So, we had a specific scenario, and this is illustrated in a figure in the paper, really showing the treatment as well as the changes in ctDNA, tumor markers, and also radiographic response. So, this particular patient was on first-line endocrine therapy and CDK4/6 inhibitor with palbociclib. Initially, she had a low-level detectable ctDNA. It became undetectable during treatment, and the patient had a couple of serial ctDNA assays that were negative, so undetectable. And then we started, after about seven months on this combination therapy, the ctDNA levels started rising. She actually had three serial ctDNA assays with increasing level of ctDNA before she even had any imaging tests. And then around the time that the ctDNA peaked, this patient had radiographic evidence of progression. There was also an NGS-based assay sent to look for specific mutations at that point. The patient was found to have an ESR1 mutation, which is very common in this patient population. She was switched to a novel oral SERD, elacestrant, and the ctDNA fell again to undetectable within the first couple months of being on elacestrant. And then a very similar thing happened: while she was on this second-line therapy, she had three serial negative ctDNA assays, and then the fourth one was positive. This was two months before the patient had a scan that showed progression again. Dr. Rafeh Naqash: And Julia, like you mentioned, this is a small sample size, limited number of patients, in this case, one patient case scenario, but provides insights into other important aspects around escalation or de-escalation of therapy where perhaps ctDNA could be used as an integral biomarker rather than an exploratory biomarker. What are some of your thoughts around that and how is the breast cancer space? I know like in GI and bladder cancer, there has been a significant uptrend in MRD assessments for therapeutic decision making. What is happening in the breast cancer space? Dr. Julia Foldi: So, super interesting. I think this is where a lot of our different fields are going. In the breast cancer space, so far, I have seen a lot of escalation attempts. It is not even necessarily in this particular setting where we are looking at dynamics of ctDNA, but in the breast cancer world, of course, we have a lot of data on resistance mutations. I mentioned ESR1 mutation in a particular patient in our study. ESR1 mutations are very common in patients with ER-positive breast cancer who are on long-term endocrine therapy, and ESR1 mutations confer resistance to aromatase inhibitors. So, that is an area that there has been a lot of interest in trying to detect ESR1 mutations earlier and switching therapy early. So, this was the basis of the SERENA-6 trial, which was presented last year at ASCO and created a lot of excitement. This was a trial where patients had non-tumor-informed NGS-based Guardant assay sent every three to six months while they were on first-line endocrine therapy with a CDK4/6 inhibitor. If they had an ESR1 mutation detected, they were randomized to either continue the same endocrine therapy or switch to an oral SERD. The trial showed that the population of patients who switched to the oral SERD did better in terms of progression-free survival than those who stayed on their original endocrine therapy. There are a lot of questions about how to use this in routine practice. Of course, it is not trivial to be sending a ctDNA assay every three to six months. The rate of detection of these mutations was relatively low in that study; again, the incidence increases in later lines of therapy. So, there are a lot of questions about whether we should be doing this in all of our first-line patients. The other question is, even the patients who stayed on their original endocrine therapy were able to stay on that for another nine months. So, there is this question of: are we switching patients too early to a new line of therapy by having this escalation approach? So, there are a lot of questions about this. As far as I know, at least in our practice, we are not using this approach just yet to escalate therapy. Time will tell how this all pans out. But I think what is even more interesting is the de-escalation question, and I think that is where tumor informed assays like Signatera and the data that our study generated can be applied. Actually, our plan is to generate some prospective data in the lobular breast cancer population, and I have an ongoing study to do that, to really be able to tease out the early ctDNA dynamics as patients first start on endocrine therapy. So, this is patients who are newly diagnosed, they are just starting on their first-line endocrine therapy, and measure, with sensitive assays, measure ctDNA dynamics in the first few months of therapy. In those patients who have a really robust response, that is where I think we can really think about de-escalation. In the patients whose ctDNA goes to undetectable after just a few weeks of therapy with just an endocrine agent, they might not even need a CDK4/6 inhibitor in their first-line treatment. So, that is an area where we are very interested in our group, and I know that other groups are looking at this too, to try to de-escalate therapy in patients who clear their ctDNA early on. Dr. Rafeh Naqash: Thank you so much. Well, lots of questions, but at the same time, progress comes through questions asked, and your project is one of those which is asking an interesting question in a rarer cancer and perhaps will lead to subsequent improvement in how we monitor these individuals and how we escalate or de-escalate therapy. Hopefully, we will get to see more of what you are working on in subsequent submissions to JCO Precision Oncology and perhaps talk more about it in a couple of years and see how the space and field is moving. Thanks again for sharing your insights. I do want to take one to two quick minutes talking about you as an investigator, Julia. If you could speak to your career pathway, your journey, the pathway to mentorship, the pathway to being a mentor, and how things have shaped for you in your personal professional growth. Dr. Julia Foldi: Sure, yeah, that is great. Thank you. So, I had a little bit of an unconventional path to clinical medicine. I actually thought I was going to be a basic scientist when I first started out. I got a PhD in Immunology right out of college and was studying not even anything cancer-related. I was studying macrophage signaling in inflammatory diseases, but I was in New York City. This was right around the time that the first checkpoint inhibitors were approved. Actually, some of my friends from my PhD program worked in Jim Allison's lab, who was the basic scientist responsible for ipilimumab. So, I got to kind of first-hand experience the excitement around bringing something from the lab into the clinic that actually changed really the course of oncology. And so, I got very excited about oncology and clinical medicine. So, I decided to kind of switch gears from there and I went back to medical school after finishing my PhD and got my MD at NYU. I knew I wanted to do oncology, so I did a research track residency and fellowship combined at Yale. I started working early on with the breast cancer team there. At the time, Lajos Pusztai was the head of translational research there at Yale, and I started working with him early in my residency and then through my fellowship. I worked on several trials with him, including a neoadjuvant checkpoint inhibitor trial in triple-negative breast cancer patients. During my last year in fellowship, I received a Conquer Cancer Young Investigator Award to study estrogen receptor heterogeneity using spatial transcriptomics in this subset of breast cancers that have intermediate estrogen receptor expression. From there, I joined the faculty at the University of Pittsburgh in 2022. So, I have been there about almost four years at this point. My interests really shifted slowly from triple-negative breast cancers towards ER-positive breast cancers. When I arrived in Pittsburgh, I started working very closely with some basic and translational researchers here who are very interested in estrogen signaling and mechanisms of resistance to endocrine therapy, and there is a large group here interested in lobular breast cancers. During my training, I was not super aware even that lobular breast cancer was a unique subtype of breast cancers, and that is, I think, changing a little bit. There is a lot more awareness in the breast cancer clinical and research community about ILC being a unique subtype, but it is not even really part of our training in fellowship, which we are trying to change. But I have become a lot more aware of this because of the research team here and through that, I have become really interested also on the clinical side. And so, we do have a Lobular Breast Cancer Research Center of Excellence here at the University of Pittsburgh and UPMC, and I am the leader on the clinical side. We have a really great team of basic and translational researchers looking at different aspects of lobular breast cancers, and some of the work that I am doing is related to this particular manuscript we discussed and the next steps, as I mentioned, a prospective study of early ctDNA dynamics in lobular patients. I also did some more clinical research work in collaboration with the NSABP looking at long-term outcomes of patients with lobular versus ductal breast cancers in some of their older trials. And so, that is, in a nutshell, a little bit about how I got here and how I became interested in ILC. Dr. Rafeh Naqash: Well, thank you for sharing those personal insights and personal journey. I am sure it will inspire other trainees, fellows, and perhaps junior faculty in trying to find their niche. The path, as you mentioned, is not always straight; it often tends to be convoluted. And then finding an area that you are interested in, taking things forward, and being persistent is often what matters. Dr. Julia Foldi: Thank you so much for having me. It was great. Dr. Rafeh Naqash: It was great chatting with you. And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

This podcast episode explores various strategies for maximizing hunting properties through effective land management, habitat improvement, and sustainable practices. The conversation delves into the importance of evaluating landscapes, managing water resources, and integrating wildlife support systems. The guest, Ben Falk, shares insights on pond design, the role of animals in fertility, and the benefits of perennial crops, emphasizing a holistic approach to land stewardship. In this conversation, the speakers delve into various aspects of sustainable land management, focusing on tree management, the use of herbicides, the dynamics of invasive species, and the human impact on ecosystems. Jon Teater and Ben discuss the importance of working with nature rather than against it, emphasizing the long-term benefits of planting trees and fostering biodiversity. The conversation also touches on the mindset shifts necessary for effective land stewardship and the legacy that current practices can leave for future generations.   takeaways Start your design with soil type and regional land use. Evaluate your property at a finer level for better management. Animal enrichment creates healthier wildlife environments. Water management is crucial for supporting life and habitats. Ponds provide multiple benefits, including recreation and wildlife support. Integrate trees and perennial crops for sustainable growth. Cows can enhance soil fertility through their natural behaviors. Thinning trees can promote better growth and health. Planting diverse species can create resilient ecosystems. Managing water resources can lead to new springs and groundwater recharge. Hardwoods can reset and manage tree populations effectively. Plums can be toxic to cattle, necessitating careful management. Nature's systems are inherently balanced and not making mistakes. Herbicides are often unnecessary; plants can manage themselves. Invasive species can be beneficial and should be understood, not eradicated. We are part of nature and can positively influence ecosystems. Planting trees is a long-term investment in the future. The act of planting trees can shift one's perspective on nature. Human impact on landscapes can create lasting legacies. Digital hygiene is important for health in a tech-driven world.   Social Links https://www.wholesystemsdesign.com/ https://www.facebook.com/wholesystemsdesign/ https://www.youtube.com/@wholesystems https://www.instagram.com/ben_falk_wsd/?hl=en https://whitetaillandscapes.com/ https://www.facebook.com/whitetaillandscapes/ https://www.instagram.com/whitetail_landscapes/?hl=en Learn more about your ad choices. Visit megaphone.fm/adchoices

This podcast episode explores various strategies for maximizing hunting properties through effective land management, habitat improvement, and sustainable practices. The conversation delves into the importance of evaluating landscapes, managing water resources, and integrating wildlife support systems. The guest, Ben Falk, shares insights on pond design, the role of animals in fertility, and the benefits of perennial crops, emphasizing a holistic approach to land stewardship. In this conversation, the speakers delve into various aspects of sustainable land management, focusing on tree management, the use of herbicides, the dynamics of invasive species, and the human impact on ecosystems. Jon Teater and Ben discuss the importance of working with nature rather than against it, emphasizing the long-term benefits of planting trees and fostering biodiversity. The conversation also touches on the mindset shifts necessary for effective land stewardship and the legacy that current practices can leave for future generations. takeawaysStart your design with soil type and regional land use.Evaluate your property at a finer level for better management.Animal enrichment creates healthier wildlife environments.Water management is crucial for supporting life and habitats.Ponds provide multiple benefits, including recreation and wildlife support.Integrate trees and perennial crops for sustainable growth.Cows can enhance soil fertility through their natural behaviors.Thinning trees can promote better growth and health.Planting diverse species can create resilient ecosystems.Managing water resources can lead to new springs and groundwater recharge. Hardwoods can reset and manage tree populations effectively.Plums can be toxic to cattle, necessitating careful management.Nature's systems are inherently balanced and not making mistakes.Herbicides are often unnecessary; plants can manage themselves.Invasive species can be beneficial and should be understood, not eradicated.We are part of nature and can positively influence ecosystems.Planting trees is a long-term investment in the future.The act of planting trees can shift one's perspective on nature.Human impact on landscapes can create lasting legacies.Digital hygiene is important for health in a tech-driven world. Social Linkshttps://www.wholesystemsdesign.com/https://www.facebook.com/wholesystemsdesign/https://www.youtube.com/@wholesystemshttps://www.instagram.com/ben_falk_wsd/?hl=enhttps://whitetaillandscapes.com/https://www.facebook.com/whitetaillandscapes/https://www.instagram.com/whitetail_landscapes/?hl=en Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Tommy Rhee is a nationally featured sports chiropractor, regenerative medicine innovator, author and speaker. He is known for challenging conventional healthcare while introducing non-invasive, needle-free solutions for healing and performance. Dr. Rhee is the founder and CEO of Rhee-Gen, a patent pending cell-free regenerative platform focused on topical biological signaling rather than injections. His work sits on the intersection of sports medicine, biotechnology, and the future of human performance. He is the author of the book titled "The Future of Regenerative Medicine: Unlocking the Potential of Topical Stem Cell Therapy" as well as a United States Navy Aircrew Veteran. Dr. Rhee has been in clinical practice since 2006 and has spent over 20 years in the regenerative medicine field, where he is widely regarded as an expert in topical regenerative therapies. With a background spanning elite sports medicine, clinical innovation, and service as a U.S. Navy aviator, Dr. Rhee offers a rare perspective on performance, recovery, and the future of regenerative care.   Dr. Rhee shares his experience and expertise along with his extensive research that went in to creating a product which can be applied topically by the patient to promote natural healing and recovery for people of all ages, from elite professional athletes to the senior weekend warrior without the risk of potential side effects of injections. He explains complex science and biology in clear, concise terms which is easy to understand and apply to practical applications for the listeners, as he gives hope to anyone who would love to experience the healing power of topical stem cell therapy. Download this uplifting and positive episode which is full of great information for anyone who would like to enjoy the benefits of stem cell therapy without the risk, the cost, and time spent in an office receiving injections. Such a fascinating conversation! Connect with Dr. Tommy:    https://rheegen.com/ https://www.facebook.com/PhysicalChiropractic/ https://www.youtube.com/@physicalchiropractictampabay https://www.instagram.com/dr.tommyrhee/ https://www.linkedin.com/in/drtommyrhee/   Want to be a guest on TheFemiNinjaProject? Send Cheryl Ilov a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/1620842117560x116520069523704300

Reker, Anika www.deutschlandfunk.de, Europa heute

The EU has added Sika deer to the list of invasive alien species of concern in Ireland. But what does this mean in practice for deer management here? Damien Hannigan of the Irish Deer Commission joins us on tonight's programme to tell us more...

What if recovery didn't have to mean pushing harder—or going under the needle? In this episode of Healthy Mind, Healthy Life, host Sayan explores how healing can become more intelligent, less invasive, and more aligned with the body's natural repair systems. Joining him is Dr. Tommy Rhee, who breaks down recovery vs. overtraining, why “push through pain” backfires, and how next-gen regenerative signaling may support longevity, mental resilience, and trust in the healing process—without aggressive intervention. About the Guest: Dr. Tommy Rhee is a sports chiropractor, author, and practitioner focused on cell-free regenerative medicine and performance recovery. He has experience spanning elite athletics, clinical work, and military service. Key Takeaways: Recovery is as essential as training—overtraining can drive chronic injury. “Aggressive recovery” can worsen compromised tissue; strategic rest matters. Regenerative medicine focuses on signals that support tissue repair. Non-invasive topical delivery may reduce risks tied to injections. Physical healing impacts mood and identity—mind, body, and purpose interact. Fasting may help some people reset habits, but approach it thoughtfully. How to Connect With the Guest: Website: https://rheegen.com/  Book: The Future of Regenerative Medicine (Amazon) Want to be a guest on Healthy Mind, Healthy Life? DM on PM - Send me a message on PodMatch DM Me Here: https://www.podmatch.com/hostdetailpreview/avik Disclaimer: This video is for educational and informational purposes only. The views expressed are the personal opinions of the guest and do not reflect the views of the host or Healthy Mind By Avik™️. We do not intend to harm, defame, or discredit any person, organization, brand, product, country, or profession mentioned. All third-party media used remain the property of their respective owners and are used under fair use for informational purposes. By watching, you acknowledge and accept this disclaimer. Healthy Mind By Avik™️ is a global platform redefining mental health as a necessity, not a luxury. Born during the pandemic, it's become a sanctuary for healing, growth, and mindful living. Hosted by Avik Chakraborty, storyteller, survivor, and wellness advocate. With over 6000+ episodes and 200K+ global listeners, we unite voices, break stigma, and build a world where every story matters.

Woollen mats are now being trialled to smother an invasive oxygen weed threatening to take over some of New Zealand's lake floors. To explain how, Northland Regional Council Biodiversity Manager Lisa Forester chats to Jesse.

After testing a pilot security camera program for three years, Austin parks have seen a drop in crime. This week, the Austin Parks and Recreation Department will ask City Council for approval to expand the program. But amid concerns about mass surveillance and data privacy, what will council do? On today's Tuesday News Roundup, host Nikki DaVaughn is joined by producers Elissa Castles and Eva Ruth Moravec to break down the potential benefits and risks of the program. Plus, the team discusses a Texas task force gearing up to combat a deadly invasive fly, and why Gov. Greg Abbott and Texas Attorney General Ken Paxton are investigating student protests. Want some more Austin news? Then make sure to sign up for our Hey Austin newsletter.  And don't forget– you can support this show and get great perks by becoming a City Cast Austin Neighbor at membership.citycast.fm  Follow us @citycastaustin You can also text us or leave a voicemail.  Interested in advertising with City Cast? Find more info HERE  Learn more about the sponsors of this February 3rd episode: City of Austin Window Nation

Biosecurity New Zealand has confirmed three more nests were found on the North Shore this week. Biosecurity New Zealand's Mike Inglis spoke to Corin Dann.

Send us a textWhile we work on bringing you new episodes of the podcast, we'd like to share one of our most popular episodes, originally aired December 29th, 2023. On “Invasive Orchids,” Caleb and James go over some of the orchids that have been classified as invasive, particularly in Hawai'i. Become a part of The Orchid Pod. Send us an email at theorchidpod@gmail.com or leave us a voicemail/text at +1-678-6ORCHID (+1-678-667-2443 - Standard rates apply)

Join us LIVE on Mondays, 4:30pm EST.A weekly Podcast with BHIS and Friends. We discuss notable Infosec, and infosec-adjacent news stories gathered by our community news team.https://www.youtube.com/@BlackHillsInformationSecurityChat with us on Discord! - https://discord.gg/bhis

This week we replay an important episode from 2 years ago in which we delved into the world of antibiotic prophylaxis for dental procedures. What are the data to support its use in the congenital heart patient? Why has this been such a difficult topic to study? What do we now know about this topic and what still remains unanswered? Given the low prevalence but dire consequences of this disease, how can investigators consider studying this topic in the future? Is there adequate equipoise to proceed with a randomized controlled trial? We speak with Advanced Imaging Fellow at Boston Children's Hospital, Dr. Francesca Sperotto of Harvard University about her recent multicenter meta-analysis of 30 studies including over one million cases of endocarditis. DOI: 10.1001/jamacardio.2024.0873

Cognition and the Science of Non-Invasive Brain Stimulation in MS – Episode 196 Cognitive changes in MS are often misunderstood. In this episode, Stephanie talks with Dr. Leigh Charvet about what cognition in MS really looks like—why processing speed, not memory loss, is the most common challenge, and why symptoms can fluctuate day to day. They break down what non-invasive brain stimulators are, how it boosts the effects of cognitive rehab, and what research shows about its impact on cognition, fatigue, cannabis use, and depression in people with MS. Disclaimer: This podcast provides general educational information. Can Do MS does not endorse, promote, or recommend any product or service associated with the content of this program

Join Daily Inter Lake reporter Taylor Inman as she goes over the week's biggest headlines for Northwest Montana. A Columbia Falls teenager is fighting to recover after a high-speed crash involving an allegedly stolen vehicle on Highway 2, leaving the community rallying around one of its standout student-athletes.Also in this episode, a former district court judge faces sentencing in a dramatic fall from grace tied to felony drug charges, and Flathead County officials approve a major upgrade for search-and-rescue operations with a new underwater drone.We'll hear what Flathead County officials are saying about the recent approval for the Sheriff's Office to purchase a new underwater drone. Plus, Montana Fish, Wildlife and Parks moves forward with an aggressive plan to eradicate invasive goldfish from a Thompson Falls pond, part of a growing effort to protect native waterways across the region.A big thank you to our headline sponsor for the News Now podcast, Loren's Auto Repair! They combine skill with integrity resulting in auto service & repair of the highest caliber. Discover them in Ashley Square Mall at 1309 Hwy 2 West in Kalispell Montana, or learn more at lorensauto.com. This summer, we followed the Brist family from their fifth-generation Montana farm to the bright lights of the Northwest Montana Fair. From early morning chores to the intensity of the show ring, their journey shows the hard work, tradition, and bittersweet goodbyes that come with raising livestock. Discover Season 4 of our Deep Dive podcast, From Farm to Fair — coming Sunday, September 21st! Visit DailyInterLake.com to stay up-to-date with the latest breaking news from the Flathead Valley and beyond. Support local journalism and please consider subscribing to us. Watch this podcast and more on our YouTube Channel. And follow us on Facebook, Instagram and X. Got a news tip, want to place an ad, or sponsor this podcast? Contact us! Subscribe to all our other DIL pods! Keep up with northwest Montana sports on Keeping Score, dig into stories with Deep Dive, and jam out to local musicians with Press Play.

Thank you to today's sponsors!- The Invasive Species Centre: Protecting Canada's land and water from invasive species- SAIL: The Ultimate Destination for your Outdoor Adventures- J&B Cycle and Marine: Your Home for all things powersports, boats, and equipment- Freedom Cruise Canada: Rent the boat, own the memories- Anglers Leaderboard: Real-time AI angling platform where everyone is welcome, and every catch counts!The Toronto Boat Show is here, and this week on Outdoor Journal Radio, we break down why this is the best time of year to buy a boat, what to look for on the show floor, and what new tech is shaping modern fishing boats.We're joined by Jean-Philippe Martin-Dubois, General Manager of Princecraft Boats, to talk about the unveiling of the new Platinum 190, how boat pricing really works at shows, ordering vs spring buying, financing options, and why aluminum construction still matters for Canadian anglers. JP also explains what buyers should actually be paying attention to beyond looks, including durability, electronics space, and long-term ownership.We also dive into a wild fishing headline as Japan's first tuna of 2026 sells for a staggering $3.2 million, why the first tuna of the year matters so much, and how tradition drives price more than quality.Plus, a listener's question sparks a debate on music while ice fishing, whether sound and vibration affect fish, and when silence might actually help you catch more.Topics covered: • Toronto Boat Show insider tips • Princecraft Platinum 190 first look • When and why to buy a boat at a show • Boat financing and rebates explained • Electronics, durability, and aluminum hull design • The $3.2 million first tuna of the year • Music vs silence while fishing • Invasive species awareness

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251396933

In 2004 invasive hornets established themselves in France, quickly they were unable to contained wreaking havoc to French bee colonies. Now, invasive hornets have been found in Tāmaki Makaurau, raising the alarm of a similar fate here if they cannot be contained. To understand the situation, I spoke to Commissioner North for Biosecurity New Zealand, Mike Ingils, about their efforts to contain these hornets and other invasive species.

Dr. Li-Meng Yan w/ The Voice of Dr. Yan – Mysterious seed packages from China arrive across multiple states, signaling a quiet form of warfare. Invasive plants threaten waterways, agriculture, and food security, while foreign land purchases near military sites raise alarms. These acts exploit deniability, erode trust, and weaken national resilience without a single shot being fired...

🧭 REBEL Rundown 🗝️ Key Points 💨 NIV = Support without a tube: CPAP, BiPAP, and HFNC improve oxygenation and reduce the work of breathing.🫁 CPAP = Continuous pressure: Best for hypoxemic patients (e.g., pulmonary edema, OSA).️ BiPAP = Two pressures (IPAP/EPAP): Great for hypercapnic failure (e.g., COPD, obesity hypoventilation).🌬️ HFNC = Heated, humidified high flow: Reduces effort, improves comfort, and enhances oxygen delivery.🩺 Supportive, not definitive: NIV stabilizes patients while the underlying cause is treated. Click here for Direct Download of the Podcast. 📝 Introduction Non-invasive ventilation (NIV) refers to respiratory support provided without endotracheal intubation. The most common modalities include continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), and high-flow nasal cannula (HFNC). These therapies aim to improve oxygenation, reduce the work of breathing, and potentially prevent invasive mechanical ventilation. 💨 CPAP and BiPAP CPAP delivers a single, continuous pressure during inspiration and expiration. This pressure (commonly 5–10 cm H₂O) helps recruit atelectatic alveoli, reduce shunt, and improve oxygenation. It is commonly used for conditions like pulmonary edema, obstructive sleep apnea, or mild hypoxemia without significant ventilatory failure.BiPAP alternates between two pressures:Inspiratory positive airway pressure (IPAP), augments tidal volume and unloads inspiratory muscles.Expiratory positive airway pressure (EPAP), maintains alveolar recruitment and improves oxygenation.The differential between IPAP and EPAP is critical for reducing hypercapnia in patients with COPD exacerbations or acute hypercapnic respiratory failure.IndicationsCPAP: hypoxemia without major ventilatory failure (e.g., cardiogenic pulmonary edema, atelectasis, OSA).BiPAP: hypercapnia with increased work of breathing (e.g., COPD exacerbation, neuromuscular weakness, obesity hypoventilation).A helpful way to conceptualize CPAP and BiPAP is through the hairdryer analogy. Imagine placing a hairdryer in your mouth: 🩺 Clinical Considerations Masks can be uncomfortable, impair secretion clearance, and limit oral intake.Some patients require sedation to tolerate NIV, but this carries risks in patients with unprotected airways.NIV is thus a high-stakes intervention requiring close monitoring.Common starting dose to understand titration, but start at the level appropriate for your patient:  IPAP 10 cm H₂O / EPAP 5 cm H₂O (“10/5”) and are titrated:Increase IPAP to improve tidal volume and CO₂ clearance.Increase EPAP to recruit alveoli and improve oxygenation.Both may be raised simultaneously if the patient is both hypoxemic and hypercapnic. 🚀 High-Flow Nasal Cannula (HFNC) H: Heated & humidified – improves mucociliary clearance, prevents airway drying, and enhances tolerance. I: Inspiratory flow – high flow meets or exceeds patient demand, reducing respiratory rate and effort.F: Functional residual capacity – modest generation of positive end-expiratory pressure (PEEP), promoting alveolar recruitment.L: Lighter – generally more comfortable and less restrictive than mask-based NIV.O: Oxygen dilution – minimizes entrainment of room air, delivering higher and more predictable FiO₂.W: Washout – flushes anatomical dead space, reducing CO₂ rebreathing.HFNC delivers heated, humidified oxygen at high flow rates (30–60 L/min) through wide-bore nasal prongs. A mnemonic, H-I-F-L-O-W, helps summarize its mechanisms:Indications: Traditionally used for acute hypoxemic respiratory failure (e.g., pneumonia), HFNC is increasingly studied for hypercapnic failure as well, with trials suggesting non-inferiority to BiPAP in select populations. Post Peer Reviewed By: Marco Propersi, DO (Twitter/X: @Marco_propersi), and Mark Ramzy, DO (X: @MRamzyDO) 👤 Show Notes Syed Moosi Raza, MD PGY 3 Internal Medicine Resident Cape Fear Valley Internal Medicine Residency Program Fayetteville NC Aspiring Pulmonary Critical Care Fellow 🔎 Your Deep-Dive Starts Here REBEL Core Cast – Pediatric Respiratory Emergencies: Beyond Viral Season Welcome to the Rebel Core Content Blog, where we delve ... Pediatrics Read More REBEL Core Cast 143.0–Ventilators Part 3: Oxygenation & Ventilation — Mastering the Balance on the Ventilator When you take the airway, you take the wheel and ... Thoracic and Respiratory Read More REBEL Core Cast 142.0–Ventilators Part 2: Simplifying Mechanical Ventilation – Most Common Ventilator Modes Mechanical ventilation can feel overwhelming, especially when faced with a ... Thoracic and Respiratory Read More REBEL Core Cast 141.0–Ventilators Part 1: Simplifying Mechanical Ventilation — Types of Breathes For many medical residents, the ICU can feel like stepping ... Thoracic and Respiratory Read More REBEL Core Cast 140.0: The Power and Limitations of Intraosseous Lines in Emergency Medicine The sicker the patient, the more likely an IO line ... Procedures and Skills Read More REBEL Core Cast 139.0: Pneumothorax Decompression On this episode of the Rebel Core Cast, Swami takes ... Procedures and Skills Read More The post REBEL Core Cast 148.0–Demystifying Non-Invasive Ventilation & HiFlow appeared first on REBEL EM - Emergency Medicine Blog.

Dr. Li-Meng Yan w/ The Voice of Dr. Yan – Mysterious seed packages from China arrive across multiple states, signaling a quiet form of warfare. Invasive plants threaten waterways, agriculture, and food security, while foreign land purchases near military sites raise alarms. These acts exploit deniability, erode trust, and weaken national resilience without a single shot being fired...

It began with exhaustion, longing, and a quiet house just after sunrise.A woman in Kentucky returns home after an early-morning airport goodbye, her body drained and her mind still wrapped around the feeling of someone who has just left. Sleep comes quickly—but what follows isn't rest. It's something sharper. More intimate. And far more unsettling.The dream feels different from the start. The world snaps into focus. Colors feel too real. Sensations linger longer than they should. And when a familiar presence appears, the comfort is immediate—almost overwhelming. This isn't fear. This is closeness. Connection. The kind that lowers your guard.But something is off. Details don't line up. Small things begin to itch at the edges of memory. A shape that doesn't quite fit. A movement that lingers too long. And then the moment fractures—leaving her caught between waking and dreaming, unable to move, forced to watch as the experience continues without her consent.What happens next is quiet. Physical. Invasive. And when she finally wakes for real, the house is exactly as it should be—silent, empty, untouched. Except for the certainty that whatever came to her that morning knew exactly how to be let in. #SleepParalysis #TrueGhostStory #ParanormalEncounter #NightTerror #ShadowFigure #LucidDreaming #CreepyExperience #SupernaturalStory #RealHaunting #ScaryPodcast #Unexplained #ParanormalPodcast Love real ghost stories? Don't just listen—join us on YouTube and be part of the largest community of real paranormal encounters anywhere. Subscribe now and never miss a chilling new story:

“What's Buggin' You” segment for Wednesday 1-7-26

A young woman institutionalized for disagreeing with her parents, a 12-year-old boy punished for daydreaming, even a Kennedy daughter silenced to protect her brother's political career – all lobotomized. These people and five others went into surgery as individuals with hopes, dreams, and personalities — and came out as complete strangers to themselves.CHAPTERS & TIME STAMPS (All Times Approximate)…00:00:00.000 = Show Open00:02:12.814 = The Man Who Could Make Dead Fish Talk00:08:48.284 = *** They Murdered Their Mothers00:21:37.851 = The Ghostly Handprint of Francis Leavy00:26:41.319 = *** Victims of Lobotomies00:37:09.950 = Listener submitted story from Michael Emmanuel Omokhuvie00:41:47.332 = Show Close*** = Begins immediately after inserted ad breakSOURCES and RESOURCES:“The Man Who Could Make Dead Fish Talk” by Sarah Murden for Georgian Era:https://weirddarkness.tiny.us/2nte76b6“The Ghostly Handprint of Francis Leavy” by Prince Petropia for Paranorms: https://weirddarkness.tiny.us/53xwm2wd, and by Adam for Mysterious Chicago: https://weirddarkness.tiny.us/yxcvw3td“They Murdered Their Mothers” by Jessika M. Thomas for Ranker: https://weirddarkness.tiny.us/kxprwkyk“The Victims of Lobotomies” by Jacob Shelton for Ranker: https://weirddarkness.tiny.us/3kuhpcxf=====(Over time links may become invalid, disappear, or have different content. I always make sure to give authors credit for the material I use whenever possible. If I somehow overlooked doing so for a story, or if a credit is incorrect, please let me know and I will rectify it in these show notes immediately. Some links included above may benefit me financially through qualifying purchases.)= = = = ="I have come into the world as a light, so that no one who believes in me should stay in darkness." — John 12:46= = = = =WeirdDarkness® is a registered trademark. Copyright ©2025, Weird Darkness.=====Originally aired: May 18, 2021EPISODE PAGE (includes sources): https://weirddarkness.com/lobotomizedABOUT WEIRD DARKNESS: Weird Darkness is a true crime and paranormal podcast narrated by professional award-winning voice actor, Darren Marlar. Seven days per week, Weird Darkness focuses on all things strange and macabre such as haunted locations, unsolved mysteries, true ghost stories, supernatural manifestations, urban legends, unsolved or cold cases, conspiracy theories, and more. Weird Darkness has been named one of the “20 Best Storytellers in Podcasting” by Podcast Business Journal. Listeners have described the show as a blend of “Coast to Coast AM”, “The Twilight Zone”, “Unsolved Mysteries”, and “In Search Of”.DISCLAIMER: Stories and content in Weird Darkness can be disturbing for some listeners and intended for mature audiences only. Parental discretion is strongly advised.#WeirdDarkness, #Lobotomy, #RosemaryKennedy, #MedicalHistory, #DarkHistory, #TrueStories, #DisturbingHistory, #MedicalHorror, #KennedyFamily, #DrWalterFreeman

Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study. We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study design, findings, and implications for patient care. Discover how this new standard of care is transforming treatment options, improving event-free survival, and overall survival rates for patients. Key topics covered in this episode included: • Overview of the Keynote-905/EV-303 study and its significance • Comparison with previous studies like the NIAGARA trial • Discussion on the side effects of EV Pembro and management strategies • The role of ctDNA in guiding post-operative therapy • Future directions in bladder cancer research and upcoming trials Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more practice-changing updates in oncology! #BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC

Habitat Podcast #364 - In today's episode of The Habitat Podcast, we are back in the studio with our good friends Erich Long and Cody Altizer! We discuss: Managing for grouse improves deer habitat across the entire property Grouse are specialists; deer benefit from the habitat they require Forest health is the foundation of all successful wildlife management Everything done for grouse benefits whitetails, not the other way around Deer thrive as generalists; grouse expose weak habitat Young forest habitat benefits deer, turkeys, birds, and pollinators Invasive species quietly destroy forest-floor wildlife habitat Responsible logging creates life, not destruction Managing from the forest floor up changes everything Grouse are a gateway species for better land stewardship And So Much More! Shop the new Amendment Collection from Vitalize Seed here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://vitalizeseed.com/collections/new-natural-amendments ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ PATREON - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon - Habitat Podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Brand new HP Patreon for those who want to support the Habitat Podcast. Good luck this Fall and if you have a question yourself, just email us @ info@habitatpodcast.com -------------------------------------------------------------------------- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon - Habitat Podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Latitude Outdoors - Saddle Hunting: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/hplatitude⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Stealth Strips - Stealth Outdoors: Use code Habitat10 at checkout ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/stealthstripsHP⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Midwest Lifestyle Properties - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/3OeFhrm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Vitalize Seed Food Plot Seed - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/vitalizeseed⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Down Burst Seeders - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/downburstseeders⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 10% code: HP10 Morse Nursery - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://bit.ly/MorseTrees⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 10% off w/code: HABITAT10 Packer Maxx - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://bit.ly/PACKERMAXX⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ $25 off with code: HPC25 First Lite - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/3EDbG6P⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LAND PLAN Property Consultations – HP Land Plans: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LAND PLANS⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Leave us a review for a FREE DECAL - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://apple.co/2uhoqOO⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Morse Nursery Tree Dealer Pricing – info@habitatpodcast.com Habitat Podcast YOUTUBE - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCmAUuvU9t25FOSstoFiaNdg⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: info@habitatpodcast.com habitat management / deer habitat / food plots / hinge cut / food plot Learn more about your ad choices. Visit megaphone.fm/adchoices

Der Indische Rotfeuerfisch breitet sich im Mittelmeer vor den Küsten Südeuropas aus und verdrängt heimische Arten vom Riff. Er frisst fast alles, was ihm vors Maul schwimmt. Lässt sich der Eindringling stoppen, indem wir ihn auf den Teller bringen? Lars Abromeit www.deutschlandfunkkultur.de, Die Reportage

Welcome to the Planet MicroCap Podcast's Due Diligence series. I'm your host, Robert Kraft. My guest today is Dan Goldberger, CEO of electroCore (NASDAQ: ECOR). electroCore is a commercial-stage neuromodulation company developing a suite of non-invasive vagus nerve stimulation devices—delivering a two-minute therapy session designed to rebalance the autonomic nervous system. Built around its nVNS platform, the company operates across three channels: prescription medical devices for headache and migraine, the fast-growing Truvaga direct-to-consumer wellness brand, and a specialized military and government division built around its ruggedized tac-stim product.   Founded in 2006 as a non-invasive alternative to implanted vagus nerve stimulators, electroCore has evolved into a multi-indication business with seven FDA authorizations for headache, serving major customers like the U.S. Department of Veterans Affairs and the UK's National Health Service. I invited Dan to the show to discuss all of this, as well as: How nVNS platform works and the science behind vagus nerve modulation electroCore's evolution from implanted alternatives to multi-channel neuromodulation The prescription business model across the VA, NHS, and managed care Truvaga's growth in the wellness market and why awareness is the primary competitor The tac-stim military program and its role as a meaningful revenue stream Strategic priorities heading into 2026—profitability, capital allocation, and commercial execution Challenges around insurance coverage and overcoming the “chicken and egg” problem The path toward becoming a $150–200 million business and the long-term vision for the platform For more information about electroCore, please visit: https://www.electrocore.com/ This podcast was recorded and is being made available by SNN, Inc. (together with its affiliates and its and their employees, “SNN”) solely for informational purposes. SNN is not providing or undertaking to provide any financial, economic, legal, accounting, tax, or other advice in or by virtue of this podcast. The information, statements, comments, views, and opinions provided in this podcast are general in nature, and such information, statements, comments, views, and opinions, and the viewing of/listening to this podcast are not intended to be and should not be construed as the provision of investment advice by SNN. The information, statements, comments, views, and opinions expressed in this podcast do not constitute and should not be construed as an offer to buy or sell any securities or to make or consider any investment or other course of action. The information, statements, comments, views, and opinions expressed in this podcast (including by guest speakers who are not officers, employees, or agents of SNN) are not necessarily those of SNN and may not be current. Reference to any specific third-party entity, product, service, materials, or content does not constitute an endorsement or recommendation by the SNN. SNN assumes no responsibility or liability for the accuracy or completeness of the content contained in third party materials or on third party sites referenced in this podcast or the compliance with applicable laws of such materials and/or links referenced herein. The views expressed by guest speakers are their own and their appearance on this podcast does not imply an endorsement of them or any entity they represent. SNN does not make any representation or warranty as to the accuracy or completeness of any of the information, statements, comments, views, or opinions contained in this podcast, which may include forward-looking statements where actual results may differ materially. SNN does not undertake any obligation whatsoever to provide any form of update, amendment, change, or correction to any of the information, statements, comments, views or opinions set forth in this podcast. SNN EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING OUT OF ANY INDIVIDUAL'S USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE, THIS PODCAST OR THE INFORMATION PRESENTED IN THIS PODCAST. By accessing this podcast, the listener acknowledges that the entire contents and design of this podcast, are the property of SNN, or used by SNN with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this podcast may save and use information contained in the podcast only for personal or other non-commercial educational purposes. No other use, including without limitation, reproduction, retransmission, or editing of this podcast may be made without the prior written consent of SNN.

Mrasek, Volker www.deutschlandfunk.de, Forschung aktuell

Pyritz, Lennart www.deutschlandfunk.de, Forschung aktuell

In this episode of the HuntFishTravel Podcast, I sit down with Amy Siewe, better known as The Python Huntress. Amy is a professional python hunter working on the front lines of conservation in Florida, helping remove one of the most destructive invasive species in North America. We talk about how she went from real estate broker to full-time python hunter, what it's actually like to hunt massive snakes in the wild, and why this work is so critical to protecting native wildlife in the Everglades. We dive deep into how Burmese pythons ended up in Florida in the first place, the impact they've had on native mammals and ecosystems, what a real python hunt looks like, from spotlighting roads at night to catching snakes by hand, the largest python Amy has ever caught and a wild story to go with it, and how python hunting ties directly into scientific research and conservation. This episode is fascinating, intense, occasionally jaw-dropping (I probably said "bananas" way too many times to count), and deeply rooted in responsible conservation. Amy's respect for wildlife and the Everglades comes through loud and clear and I walked away with a whole new understanding of just how serious the python problem really is. Whether you're a hunter, angler, conservationist, or just someone who loves wild stories from the field, this is an episode you don't want to miss. Learn more or book a hunt: pythonhuntress.com Follow Amy's adventures: @thepythonhuntress on Instagram and @pythonhuntress on Facebook. Timestamps: 00:00 – 01:24 – Opening intro & setting the Everglades scene 01:24 – 02:37 – Meet Amy Siewe, The Python Huntress 02:37 – 04:05 – How Amy became a professional python hunter 04:05 – 05:48 – From thrill-seeking to conservation mission 05:48 – 07:16 – How Burmese pythons invaded Florida 07:16 – 08:47 – Population explosion & lack of predators 08:47 – 10:22 – How big pythons get (and how dangerous they could be) 10:22 – 12:18 – What pythons eat & ecosystem collapse 12:18 – 14:17 – Why the Everglades are the perfect python habitat 14:17 – 15:55 – How python hunts actually work 15:55 – 16:18 – Catching pythons by hand 16:18 – 17:30 – Spotting snakes at night 17:30 – 24:46 – The 17-foot, 110-pound python story 24:46 – 26:39 – Why live capture is necessary 26:39 – 29:07 – Research, data, and working with biologists 29:07 – 30:44 – Hair-raising moments in the field 30:44 – 31:39 – Licensing, legality, and invasive species rules 31:39 – 33:29 – Ethics, conservation, and respecting wildlife 33:29 – 35:25 – Booking a hunt & following Amy online 35:25 – 36:03 – Final thoughts & wrap-up  

Die Quagga-Muschel stammt aus dem Schwarzmeerraum, macht sich aber auch in Deutschland breit. Im Chiemsee zum Beispiel entzieht sie dem Wasser wichtige Nährstoffe. Wie lassen sich diese invasiven Arten stoppen? Die Möglichkeiten sind begrenzt. Thiele, Marlene www.deutschlandfunk.de, Hintergrund

Revisiting a conversation from August 2023 with Dr. Bethany Bradley of the University of Massachusetts, who describes how plants introduced from outside our ecosystems may remain quiescent for decades before turning invasive, and how climate change is threatening to explode this threat.

Decades ago, non-native carp were brought onto fish farms on the Mississippi River to control algae and parasites. They escaped, thrived, and eventually flooded the Illinois River, outcompeting native species and wreaking havoc. If the carp find their way into the Great Lakes, they could do major damage to those vital ecosystems.There's a proposed project to stop the fish—but it's expensive, and not everyone agrees it's the best solution. Host Flora Lichtman speaks with WBEZ and Grist reporter Juanpablo Ramirez-Franco and carp expert Cory Suski.Guests: Juanpablo Ramirez-Franco is an environmental reporter at WBEZ and Grist. Dr. Cory Suski is a professor of aquatic resources at the University of Illinois.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.